Advertisement

Reactions Weekly

, Volume 1732, Issue 1, pp 117–117 | Cite as

Ceftolozane/tazobactam

Development of resistance during treatment of Pseudomonas aeruginosa infection: 8 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a prospective observational study of 58 patients performed between May 2016 and September 2017, eight patients [ages and sexes not stated] were described, who developed resistance to ceftolozane/tazobactam during treatment of multidrug resistant Pseudomonas aeruginosa infection [routes, duration of treatments to reactions onset and outcomes not stated; not all doses stated].

Patient 1: A patient, who had multidrug resistant Pseudomonas aeruginosainfection, received treatment with ceftolozane/tazobactam along with meropenem, ceftazidime and amikacin. The dose of ceftolozane in ceftolozane/tazobactam was reported as 1g. A sample bronchial aspirate isolated on 18 Jul 2016 showed minimum inhibitory concentration (MIC) of ceftolozane/tazobactam 4 mg/L and on 31 Jul 2016 MIC of...

Reference

  1. Diaz-Canestro M, et al. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. European Journal of Clinical Microbiology and Infectious Diseases 37: 2191-2200, No. 11, Nov 2018. Available from: URL: http://doi.org/10.1007/s10096-018-3361-0 - SpainCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations